Ayelet Zlotogorski-Hurvitz1, Dan Dayan1, Gavriel Chaushu2, Tuula Salo3,4,5, Marilena Vered6,7. 1. Department of Oral Pathology and Oral Medicine, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel. 2. Department of Oral and Maxillofacial Surgery, School of Dental Medicine, Tel Aviv University and Department of Oral and Maxillofacial Surgery, Rabin Medical Center, Petah Tikva, Israel. 3. Departments of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu and Oulu University Hospital, Oulu, Finland. 4. Medical Research Center, Oulu, Finland. 5. Institute of Dentistry, University of Helsinki, Helsinki, Finland. 6. Department of Oral Pathology and Oral Medicine, School of Dental Medicine, Tel Aviv University, Tel Aviv, Israel. lmy@netvision.net.il. 7. Institute of Pathology, The Chaim Sheba Medical Center, Tel Hashomer, Israel. lmy@netvision.net.il.
Abstract
PURPOSE: Oral cancer (OC) patients are at high risk to develop recurrent disease or secondary primary cancers with no available biomarkers to detect these events until a visible lesion is readily present and diagnosed by biopsy. Exosomes secreted by cancer cells are involved in tumor growth, invasion and metastasis. We aimed to determine morphological and molecular differences between oral fluid (OF)-derived exosomes of OC patients and those isolated from healthy individuals (HI). METHODS: OF from OC patients (n = 36) and HI (n = 25) was initially assessed by nanoparticle tracking analysis (NTA). Following ultracentrifugation, exosomal pellets of OC patients and HI were morphologically examined by transmission electron microscopy and atomic force microscopy (AFM). Enzyme-linked immunosorbent assay (ELISA) and western blotting (WB) were used to analyze the expression of exosomal markers--CD9, CD81 and CD63. RESULTS: NTA showed that OC samples of OF had a significantly higher concentration of nanoparticles/ml (p = 0.01) and modal nanoparticle size (p = 0.002) compared to HI. The difference in size was structurally highlighted by AFM three-dimensional images applied on exosomal pellets. ELISA and WB showed differential expression of exosomal markers in OC exosomes compared to HI: lower expression of CD81 and CD9 in contrast to a higher expression of CD63 (~53 kDa). CONCLUSIONS: OF-derived exosomes from OC patients differ both morphologically and molecularly from exosomes present in HI. This study is a baseline that provides a starting point for finding exosomal biomarkers for early detection of malignant changes in high-risk patients without overt clinical signs/lesions.
PURPOSE:Oral cancer (OC) patients are at high risk to develop recurrent disease or secondary primary cancers with no available biomarkers to detect these events until a visible lesion is readily present and diagnosed by biopsy. Exosomes secreted by cancer cells are involved in tumor growth, invasion and metastasis. We aimed to determine morphological and molecular differences between oral fluid (OF)-derived exosomes of OC patients and those isolated from healthy individuals (HI). METHODS: OF from OC patients (n = 36) and HI (n = 25) was initially assessed by nanoparticle tracking analysis (NTA). Following ultracentrifugation, exosomal pellets of OC patients and HI were morphologically examined by transmission electron microscopy and atomic force microscopy (AFM). Enzyme-linked immunosorbent assay (ELISA) and western blotting (WB) were used to analyze the expression of exosomal markers--CD9, CD81 and CD63. RESULTS: NTA showed that OC samples of OF had a significantly higher concentration of nanoparticles/ml (p = 0.01) and modal nanoparticle size (p = 0.002) compared to HI. The difference in size was structurally highlighted by AFM three-dimensional images applied on exosomal pellets. ELISA and WB showed differential expression of exosomal markers in OC exosomes compared to HI: lower expression of CD81 and CD9 in contrast to a higher expression of CD63 (~53 kDa). CONCLUSIONS: OF-derived exosomes from OC patients differ both morphologically and molecularly from exosomes present in HI. This study is a baseline that provides a starting point for finding exosomal biomarkers for early detection of malignant changes in high-risk patients without overt clinical signs/lesions.
Authors: Angélique Bobrie; Sophie Krumeich; Fabien Reyal; Chiara Recchi; Luis F Moita; Miguel C Seabra; Matias Ostrowski; Clotilde Théry Journal: Cancer Res Date: 2012-08-03 Impact factor: 12.701
Authors: Susana Ovalle; María Dolores Gutiérrez-López; Nieves Olmo; Javier Turnay; María Antonia Lizarbe; Pedro Majano; Francisca Molina-Jiménez; Manuel López-Cabrera; María Yáñez-Mó; Francisco Sánchez-Madrid; Carlos Cabañas Journal: Int J Cancer Date: 2007-11-15 Impact factor: 7.396
Authors: Jopi J W Mikkonen; Surya P Singh; Ramin Akhi; Tuula Salo; Reijo Lappalainen; Wilfredo A González-Arriagada; Márcio Ajudarte Lopes; Arja M Kullaa; Sami Myllymaa Journal: Oncol Lett Date: 2018-09-07 Impact factor: 2.967